Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Poolbeg Pharma PLC

Healthcare GB POLB

8.4GBX
-0.1(1.18%)

Last update at 2026-06-04T15:39:00Z

Day Range

7.908.60
LowHigh

52 Week Range

2.405.20
LowHigh

Fundamentals

  • Previous Close 8.50
  • Market Cap30.32M
  • Volume5771546
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.80400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5.94400M -4.50500M -4.77700M -2.33600M
Minority interest - - - -
Net income -5.79000M -3.93100M -4.68600M -2.33600M
Selling general administrative 5.26M 3.38M 3.06M 2.03M
Selling and marketing expenses - 3.35M - -
Gross profit -0.11400M -0.02600M 0.00000M 0.00000M
Reconciled depreciation 0.11M 0.03M 0.03M 0.02M
Ebit -6.11100M -4.68600M -4.98600M -2.33600M
Ebitda -5.99700M -4.66000M -4.96000M -2.31800M
Depreciation and amortization 0.11M 0.03M 0.03M 0.02M
Non operating income net other - - - -
Operating income -6.61800M -5.03900M -4.98600M -2.33600M
Other operating expenses 6.37M 5.04M 4.99M 2.34M
Interest expense - - - 0.00000M
Tax provision -0.15400M -0.57400M -0.09100M 0.00000M
Interest income 0.43M 0.53M 0.21M 0.00000M
Net interest income 0.43M 0.53M 0.21M 0.00000M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.15M -0.57400M -0.09100M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 6.37M 5.04M 4.99M 2.34M
Cost of revenue 0.11M 0.03M 0.00000M 0.00000M
Total other income expense net 0.67M 0.53M 0.21M -
Discontinued operations - - - -
Net income from continuing ops -5.79000M -3.93100M -4.68600M -2.33600M
Net income applicable to common shares - - -4.68600M -3.11467M
Preferred stock and other adjustments - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.25M 15.43M 19.29M 23.02M
Intangible assets 1.68M 1.93M 2.13M 1.56M
Earning assets - - - -
Other current assets 0.22M 0.63M - -
Total liab 0.97M 0.99M 0.97M 0.44M
Total stockholder equity 9.27M 14.44M 18.32M 22.58M
Deferred long term liab - - - -
Other current liab 0.74M 0.85M - 0.00300M
Common stock 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M
Retained earnings -16.74300M -10.95300M -7.02200M -2.33600M
Other liab - - - -
Good will - - - -
Other assets - 0.00000M - -
Cash 7.82M 12.17M 16.19M 20.95M
Cash and equivalents - - - -
Total current liabilities 0.97M 0.99M 0.97M 0.44M
Current deferred revenue - - - -
Net debt -7.82400M -12.17100M -16.19300M -20.94900M
Short term debt - - - -
Short long term debt - - - -
Short long term debt total - - - -
Other stockholder equity 23.10M 24.55M 25.25M 24.82M
Property plant equipment - - - -
Total current assets 8.56M 13.50M 17.16M 21.45M
Long term investments - - - -
Net tangible assets - - 16.19M 21.02M
Short term investments - - - -
Net receivables 0.52M 0.70M 0.96M 0.06M
Long term debt - - - -
Inventory - -1.32700M - -
Accounts payable 0.17M 0.08M 0.97M 0.44M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 2.82M 0.74M - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - 1.93M - -
Deferred long term asset charges - - - -
Non current assets total 1.68M 1.93M 2.13M 1.56M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.30M 0.36M -0.38800M -0.08100M
Change to liabilities - - 0.53M 0.58M
Total cashflows from investing activities 0.30M 0.36M -0.38800M -0.10800M
Net borrowings - - - -
Total cash from financing activities - - - 23.18M
Change to operating activities - - - -
Net income -5.94400M -3.93100M -4.77700M -2.33600M
Change in cash -4.34700M -4.02200M -4.75600M 20.95M
Begin period cash flow 12.17M 16.19M 20.95M 0.00000M
End period cash flow 7.82M 12.17M 16.19M 20.95M
Total cash from operating activities -4.64600M -4.38100M -4.36800M -2.14600M
Issuance of capital stock - - 0.00000M 23.18M
Depreciation 0.11M 0.03M 0.03M 0.02M
Other cashflows from investing activities 0.43M 0.36M 0.21M 0.21M
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables 0.15M 0.00021M -0.45600M -0.67467M
Sale purchase of stock - - - -
Other cashflows from financing activities - 0.36M -0.38800M 0.23M
Change to netincome - - 0.22M 0.32M
Capital expenditures 0.13M 0.17M 0.60M 0.08M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.14M 0.00021M 0.07M -0.06800M
Stock based compensation 0.62M 0.00005M 0.43M 0.24M
Other non cash items 0.43M -0.47626M -0.11800M -
Free cash flow -4.77500M -4.02200M -4.96500M -2.22700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
POLB
Poolbeg Pharma PLC		 -0.1 1.18% 8.40 - - - 2.51 -6.5923
GNS
Genus PLC		 38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Poolbeg Pharma PLC

40 Bank Street, London, United Kingdom, E14 5NR

Key Executives

Name Title Year Born
Dr. Jeremy Skillington Ph.D. CEO & Director NA
Mr. Ian O'Connell CFO & Director NA
Mr. Salim Hamir F.C.A. Company Sec. NA
Mr. Ross Crockett Group Financial Controller NA
Mr. Cathal Martin Friel Executive Chairman of The Board 1964
Dr. Jeremy Skillington Ph.D. CEO & Director 1971
Mr. Ian O'Connell CFO & Director 1987
Carol Dalton Vice President of Investor Relations & Public Relations NA
Mr. Liam Tremble Principal Scientist NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.